MDGL250117P120000
- 2.30
- 0.000.00%
Madrigal Pharmaceuticals Newsroom
Leerink Partners Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
Sagimet Started at Outperform by Oppenheimer, MASH Drug Cited
Madrigal Pharmaceuticals Price Target Raised to $427 From $415 at JMP Securities
Madrigal Pharmaceuticals Insider Sold Shares Worth $1,135,122, According to a Recent SEC Filing
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Path To Profitability
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Madrigal Pharmaceuticals (MDGL)
Top 3 Health Care Stocks That May Dip This Month
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move
Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024?
Oppenheimer Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $400
Trump Media Saw the Largest Increase in Short Interest in October
Cantor Fitzgerald Reiterates Neutral on Madrigal Pharmaceuticals
TD Cowen Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
Watching Madrigal Pharmaceuticals; Traders Circulate Unconfirmed Rumor From M&A Blog That The Co May Be Seeing Takeover Interest
Paulson & Co. Exits AngloGold Ashanti, Boosts Madrigal Pharma Among Q3 Moves
Express News | Rtw Investments, LP Reports 9.2% Passive Stake in Madrigal Pharmaceuticals Inc as of Sept 30, 2024- SEC Filing
Sagimet Draws Buy at UBS on MASH Opportunity
Here's Why Madrigal (MDGL) Is a Great Momentum Stock to Buy
Shareholders Have Faith in Loss-making Madrigal Pharmaceuticals (NASDAQ:MDGL) as Stock Climbs 55% in Past Week, Taking Three-year Gain to 267%
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences